pharmaceutical or biopharmaceutical; principal mode of action is chemical rather than structural, like a device.
Type 1 diabetes is still treated with insulin injections. Insulin is supplied in a variety of long, intermediate and short-acting preparations. The duration of action of insulin preparations required to give optimal control varies from patient to patient. This means that individual patients are established on particular regimens which are not changed unless they are [...]
(See PRLog press release at link.) As well established as the practices are for the management of types 1 and 2 diabetes, a raft of new technologies, from modest to radical, are steadily entering clinical practice and the industry, according to a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug [...]
The desirability of close glucose control, highlighted by the Diabetes Control and Complications Trial (DCCT), led many diabetics to undertake multiple daily injections (MDI) to improve their diabetes management. But for some, this meant a heightened risk of hypoglycemic episodes. Insulin pumps had been available for some time and they now offered a possible means [...]
Competition in the field of tissue engineering and cell therapy is intense, whether it be attracting top scientists, obtaining licenses to university-owned patents, being the first to reach market with a particular technology, obtaining coveted investment funding, or gaining the attention of larger companies with deeper pockets. With new companies being founded every day, competition [...]
At a pediatric diabetes conference I attended some six years ago, there was a presentation on pancreatic cell transplantation by a well regarded researcher. Having myself come from a background in biotechnology, and then as now being convinced of the potential of biotechnology in medicine, I inquired about the prospects for cell transplantation for diabetes. [...]
The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
The number of competitors developing and marketing cell therapy and tissue engineering products is extraordinary. But since approved clinical applications are proliferating and the resulting market has been driving dramatic double-digit-plus growth, it's unsurprising that competitors from extreme sides of the medical technology industry — drug, device, and biotech — are converging on this lucrative [...]
Options for drug-eluting stent (DES) manufacturers to differentiate their products include stent material, stent shape, drug-deposition methods and others, but most importantly the drug itself. The first drug employed in drug-eluting stents was sirolimus in J&J's CYPHER stent, followed by Boston Scientific with its paclitaxel-coated TAXUS stent. Since then (2003), the options for drug coatings [...]
In medical technology development, there are perennially long-shot technologies being pursued for their ability to make an order of magnitude shift in treatment. This, of course, seems to be the thrust of a majority of biotechnology development, which seeks to provide cures where only palliative treatments (drug or device) currently exist, such as in gene [...]
A steady rate of technology development in coronary stents, producing an equally steady stream of new stent market introductions, is focused on expanding aggregate stent caseload (through penetration of what would otherwise be coronary artery bypass caseload) or shifting the balance even further toward concentration of stents sales to the drug-eluting stent (DES) variety. While [...]
Contact:
